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Disruptions in sleep and sleep–wake cycle
regulation have been identified as one of the main
causes for the pathophysiology of depressive
disorders. The search has been on for the
identification of an ideal antidepressant that could
improve both sleep disturbances and depressive
symptomatology. Melatonin, the major hormone of
the pineal gland, has been shown to improve sleep
and is involved in the regulation of the sleep–wake
cycle. Identification of high concentrations of MT1
and MT2 melatonergic receptors in the
suprachiasmatic nucleus of the anterior
hypothalamus, the structure concerned with
regulation of circadian rhythms and sleep–wake
cycles, has led to the development of melatonergic
agonists with greater potency and longer durations
of action. Agomelatine is one such melatonergic
agonist that acts specifically on MT1/MT2
melatonergic receptors and at the same time exhibits
5-HT2C antagonism, a property that is utilized by
current antidepressants that are in clinical use.
Agomelatine has been shown to be effective in
a number of animal models of depression. Clinical
studies undertaken on patients with major
depression, bipolar disorders, seasonal affective
disorder, and generalized anxiety disorder have all
shown that agomelatine is also very effective in
ameliorating depressive symptoms and manifesting
early onset of action with a good tolerability and
safety profile. It improved sleep efficiency and also
resynchronized the disrupted circadian rhythms.
Hence, the melatonergic modulation by agomelatine
is suggested as one of the mechanisms for its
antidepressant effect. Agomelatine’s action on
dendritic neurogenesis in animal models of
depression is also identified as yet another action.
(The Journal of Neuropsychiatry and Clinical
Neurosciences 2012; 24:290–308)
D epressive disorders constitute a heterogeneousgroup of disorders and involve complex interac-
tions of genetic and environmental factors. Among the
physiological factors that trigger this disease, distur-
bances of circadian and sleep–wake cycles, as well as
abnormalities of melatonin secretion, have become the
primary focus of attention1 and formed the basis for the
development of effective pharmacotherapeutic agents
for treating this disease. Pharmacotherapy for treatment
of depressive disorders have been in use since the 1950s,
and includes tricyclic antidepressants (TCAs), monoamine
oxidase inhibitors (MAOIs), serotonin–norepinephrine
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reuptake inhibitors (SNRIs), and selective serotonin re-
uptake inhibitors (SSRIs). All these antidepressants act
through manipulations of monoaminergic neurotrans-
mitter pathways in the brain and have been effective in
causing remission of depressive symptoms in most of
the clinical trials undertaken.2–4 These drugs constitute
the third most widely used class of antidepressants
worldwide, with SSRIs alone accounting for 80% of the
total market share.5 With intensive epidemiological and
EEG studies identifying “sleep and sleep–wake distur-
bances” as the most important underlying factor for the
pathophysiology of depressive disorders,6 the focus has
shifted toward developing new classes of antidepres-
sants that can correct the underlying abnormalities in
sleep and circadian rhythms seen in patients with major
depressive disorder (MDD) and bipolar disorders. Reports
of significant correlations between low melatonin pro-
duction and insomnia7–9 suggest the possible relationship
between melatonin and sleep. Use of slow-release melato-
nin in patients with depressive disorders improved sleep
quality, but exerted only weak antidepressant effects.10
Development of a new synthetic analog of melatonin,
namely agomelatine, a specific agonist of MT1 and MT2
melatonin receptors and a selective antagonist to 5-HT2C
receptors,11 has been shown to have significant antide-
pressant properties.12 Following these findings, the anti-
depressant efficacy of agomelatine has been demonstrated
in a number of clinical studies undertaken in Europe, and it
has been supported by earlier review studies.13–17
MELATONIN: ITS BIOSYNTHESIS
AND METABOLISM
Melatonin biosynthesis occurs mainly in the pineal gland
of all vertebrates, with highest secretion occurring only
during dark hours of the night, and its synthesis in the
pineal gland is regulated by the suprachiasmatic nu-
cleus (SCN) of the hypothalamus. Environmental light,
which acts as the major zeitgeber, synchronizes the pineal
melatonin secretion with the 24 hours of the light–dark
cycle.18 Besides the pineal gland, melatonin is also synthe-
sized by other organs, such as the retina,19 gastrointestinal
tract,20 skin,21 lymphocytes,22 thymus,23 and many other
areas in the body. However, circulating melatonin is
derived mainly from the pineal gland. The biosynthetic
pathway of melatonin is shown in Figure 1. Once formed,
melatonin is released either into blood capillaries, or di-
rectly into the cerebrospinal fluid.24 Melatonin has a very
short half-life of about 20 to 30 minutes.25 Circulating
melatonin is metabolized in the liver by hepatic cyto-
chrome P450 (CYP) mono-oxygenases, followed by conju-
gation to form 6-hydroxy-melatonin, which is the main
urinary metabolite, aMT6s; but in neural tissues, the pri-
mary cleavage product is N1-acetyl-N2–formyl-5-methoxy-
kynuramine (AFMK), which can be further decomposed
to form N1-acetyl-5-methooxy-kynuramine (AMK).26
MELATONIN RECEPTORS
Except for its free-radical scavenging actions, all other
physiological effects of melatonin in the body are at-
tributed to the presence of specific membrane-bound
MT1 and MT2 melatonin receptors, cytosol receptors, or
nuclear receptors like RZR/RORa orphan receptors. The
two membrane-bound receptors, MT1 and MT2, are
G-protein receptors and have been cloned and charac-
terized.27,28 MT1 receptor activation leads to adenylyl
cyclase inhibition and phospholipase Cb activation.29
MT2 receptor activation leads to a number of signal-
transduction pathways, like phosphoinositide produc-
tion, inhibition of adenylyl cyclase, and inhibition of the
guanylyl cyclase pathway.30
MT1 and MT2 melatonin receptors are expressed in
various tissues of the body, either separately or together.
Of these various sites, the presence of MT1 and MT2
melatonin receptors in the SCN is of functional impor-
tance for regulation of the sleep–wake cycle and, hence,
for discussing the possible role of melatonergic recep-
tors and melatonergic drugs used for the treatment of
insomnia, circadian rhythm, and depressive disorders.31
MELATONIN, DEPRESSIVE DISORDERS,
AND SLEEP DISTURBANCES
It is well known that patients with either major de-
pressive disorder or bipolar disorders exhibit marked
difficulties in the initiation and maintenance of sleep,
poor quality of sleep, and frequent early-morning awak-
enings.32–34 Also, the temporal distribution of REM
sleep is typically altered during overnight sleep in
depression, and this abnormality in the timing of the
REM/non-REM cycle is attributed to the disorganized
nature of the pathways that regulate the sleep–wake
cycle.34 The National Institute of Mental Health (NIMH)
Epidemiologic Catchment Area (ECA) study of sleep
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disturbances and psychiatric disorders has identified
sleep disturbance as a highly significant risk factor for
subsequent development of depression.35 Hence, persis-
tent sleep abnormalities should be addressed first in
treating depressive symptomatology.36,37 A comprehen-
sive program of therapy for depressive disorders should
depend not only on clinical and behavioral symptoms,
but also on the sleep and circadian rhythm disturbances
of depressive disorders.38,39 Accordingly, an ideal anti-
depressant should decrease sleep-onset latency, de-
crease the number of awakenings after sleep onset, and
should increase alertness during daytime.40 Currently,
SSRIs constitute 80% of all prescription antidepressants,5
but they have been found to exacerbate the sleep
FIGURE 1. Biosynthesis of Melatonin
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disturbances, and one-third of the patients receiving
SSRIs also receive concomitant sedative-hypnotics.41 Use
of these sedative-hypnotics, consisting of benzodiazepine
or nonbenzodiazepine drugs, can also result in many
adverse effects, such as rebound insomnia, cognitive and
memory impairment, dependency, and so on. Also, all the
conventional antidepressants that are in use today (TCAs,
MAOIs, SNRIs, SSRIs) elevate daytimemood by activating
CNS mechanisms. If these energizing effects are sustained
at night, they can very much reduce sleep efficiency and
quality.42 Hence, an ideal antidepressant, while elevating
the mood during daytime, should also preserve the quality
of sleep at night.43 Agomelatine, a melatonergic agonist
developed by Servier Laboratories, France, with a high
affinity for MT1 and MT2 melatonergic receptors, and
antagonism of 5-HT2C receptors, has demonstrated its
potential as an antidepressant in a number of preclinical
studies and has also proved its clinical efficacy in patients
with depressive disorders. This review will present the
findings on agomelatine’s actions in animal models of
depression as well as its clinical efficacy in patients with
depressive disorders.
AGOMELATINE: CHEMISTRY
AND PHARMACODYNAMICS
Agomelatine has structural similarities to melatonin and is
a napthalenic compound (Figure 2) chemically designated
as N-[2-(7-methoxynaphth-1-yl)ethyl]acetamide. Its molec-
ular formula is C15 H17 NO2.
44 Agomelatine has a short
half-life of about 2 hours in human beings. It is rapidly
absorbed from the gastrointestinal tract and immediately
transported to the liver, where it is metabolized by three
CYP isoenzymes: CYPA1, CYPA2, and CYP2C9. Four
metabolites of agomelatine, namely, 3-hydroxy-S20098,
3-hydroxy-7-methyl-S20098, 7-desmethyl-S20098, and
dihydrodiol-S20098 have been identified.45 On the basis
of receptor-binding studies with more than 80 receptors
and enzymes, it was concluded that agomelatine demon-
strates significant affinity to MT1 and MT2 receptors, with
overall selectivity of .100-fold.46 Agomelatine exhibits
antagonism to 5-HT2C and 5-HT2B receptors.
11,47 Agome-
latine has no significant affinity to muscarinic, histamin-
ergic, adrenergic, or dopaminergic receptors.11 Because
agomelatine increased levels of dopamine only in the fron-
tal cortex, but not in the nucleus accumbens or striatum, it is
suggested that agomelatine exerts 5-HT2C antagonism on
dopaminergic and noradrenergic cortico-limbic pathways.48
AGOMELATINE’S ANTIDEPRESSANT EFFECTS:
PRECLINICAL STUDIES
Agomelatine has demonstrated its antidepressant activ-
ity in several animal models of depression, such as the
forced swimming test,49 psychosocial stress model,50
learned-helplessness model,12 transgenic mouse mod-
el,46,51 and chronic mild stress model.52 The antidepres-
sant activity of agomelatine in various animal models
of depression is summarized in Table 1. The forced-
swimming model has been used for assessing the anti-
depressant activity of a number of drugs. In this test,
rodents are forced to swim in a situation where they
cannot escape, as a result of which they become im-
mobile, floating in an upright posture.50 This is a
validated test for antidepressant activity.
The acute administration of agomelatine either oral-
ly or intraperitoneally to rats or mice at 4 mg/kg,
16 mg/kg, or 32 mg/kg doses significantly decreased
the duration of immobility in all the doses tested
in rats.49 But in mice, only repeated doses of ago-
melatine induced antidepressant-like effects in the
forced-swimming model. The mechanism of antidepres-
sant effect seen in this study was attributed to 5-HT2C
antagonism and to action on melatonin receptors.49 The
sucrose-consumption test after mild stress is used as one
of the animal models of depression. By using this animal
model, it was shown that administration of agomelatine
at 10 mg/kg or 50 mg/kg doses counteracted the stress-
induced decrease in sucrose consumption. Agomelatine
was found to be more potent than melatonin in this
antidepressant model. The role of MT1 and MT2
melatonergic receptors in mediating the antidepressant
effect was evaluated by concomitant administration of
the MT1/MT2 receptor-antagonist S22153, which in-
hibited the antidepressant effect of both agomelatine
and melatonin and suggested the involvement of MT1/
MT2 melatonergic receptors in mediating the antide-
pressant response.51,52 In the learned-helplessness model
test, the number of escape failures is evaluated to assess
antidepressant efficacy. By using this model, the effects
of agomelatine, imipramine, melatonin, and a selective
5-HT2C antagonist were evaluated, and the effects of
agomelatine were compared with other agents. Agome-
latine (10 mg/kg BW) was given for 5 days once or twice
daily, and the effects of pretreatment with S22153
(a melatonin-receptor antagonist; 20 mg/kg BW) were
studied. A deficit in avoidance-learning was observed,
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but administration of agomelatine alone (10 mg/kg/
BW) administered once a day significantly reduced this
deficit. Because the effects of agomelatine were canceled
by S22153 and not by SB-242084 (the 5-HT2C receptor
antagonist), it is suggested that melatonin receptors are
involved in the mediation of agomelatine’s antidepres-
sant effect.53,54
The transgenic mouse model with decreased glucocor-
ticoid receptor (GR) expression is used for studying the
antidepressant effects of drugs. Behavioral changes using
the Porsolt forced-swim test and elevated plus-maze test
were assessed in transgenic mice after administration of
either agomelatine 10 mg/kg, melatonin 10 mg/kg, or
desipramine 10 mg/kg. Drugs were injected intraperito-
neally for the total period of 21 to 42 days, 2 hours before
the onset of the dark period. Agomelatine reversed the
decreased mobility in the forced-swimming test, and the
same effect was noted with melatonin or desipramine.
Even in the elevated plus-maze test, agomelatine re-
versed the behavioral changes.51 The number of open-
arm entries and total time spent were greatly reduced by
agomelatine. In the same study, it was also noted that,
after a phase-shift, agomelatine accelerated the phase-
shift much more efficiently than melatonin, thereby
showing its efficient resynchronizing effect, which indi-
cates the therapeutic efficacy of agomelatine in treating
depressive disorders.51
Depression is suggested to be due to desynchroniza-
tion of various bodily rhythms, and correcting this
underlying abnormality is thought to be critically im-
portant in correcting this disorder. The resynchronizing
effect of agomelatine on disturbed circadian rhythms
in experimental animals has also been studied earlier,
and the effects of agomelatine on re-entrainment of
disturbed circadian rhythms as studied by various
investigators are presented in Table 1.55–60 The effects
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TABLE 1. Agomelatine: Its Chronobiotic and Antidepressant Effects in Experimental Animals
Type of Study Animal Agomelatine Dose (mg/kg) Comparison With Other Drugs N Animals Agomelatine Effect References
Animal model Long-Evans
rats
1 mg and 3 mg/kg Melatonin 1 mg/kg 24 Phase-advanced the activity Armstrong et al.,
199356
Animal model Rats 1 mg/kg–100 mg/kg Melatonin Unspecified Altered rat activity rhythms Redman et al.,
199555
Animal model Long-Evans
rats
0.5 mg.kg–10 mg/kg Melatonin 8 mg/kg 106 Re-entrained free running
rhythms
Martinet et al.,
199657
Animal model Long-Evans
hooded rats
1 mg/kg–10 mg/kg _ 52 Entrainment of circadian rhythms Redman &
Francis, 199858
Animal model Long-Evans
rats
50 mg/kg and 100 mg/kg Melatonin 50 mg/kg and 100
mg/kg
110 Entrained free running rhythms Pitrosky et al.,
199959
Animal model Golden
hamsters
20 mg/kg _ 24 Accelerated resynchronization
of circadian rhythms by 25%
Weibel et al.,
200060
Chronic mild
stress
Male Wistar
rats
10 mg/kg–50 mg/kg _ _ Reversed induced sucrose
consumption test
(antidepressant effect)
Papp et al., 200352
Forced-
swimming test
Rats and mice _ Melatonin 4 mg/kg, 8 mg/kg,
16 mg/kg, 32 mg/kg , and
64 mg/kg
10 mice per group;
4 and 6 rats per
group
Decreased duration of immobility
(antidepressant effect)
Bourin et al.,
200449
Animal model of
depression
Transgenic
mice
10 mg/kg Melatonin 10 mg/kg;
desipramine 10 mg/kg
185 Effective in reversing transgenic
mouse behavioral changes (all
three drugs)
Barden et al.,
200551
Animal model of
depression
Wistar rats 10 mg/kg and 30 mg/kg Melatonin 3 mg/kg and 10
mg/kg; fluvoxamine 4mg/kg
10 per group Increased number of choices of
large, delayed reward
(antidepressant effect)
Loiseau et al.,
200563
Animal model of
depression
Wistar rats 2 mg/kg, 10 mg/kg, 50 mg/
kg, and 100 mg/kg
Melatonin 2 mg/kg, 10 mg/kg,
and 50 mg/kg
40 per group Pretreatment with agomelatine
decreased number of escape
failures and exerted
antidepressant effect
Bertaina-Anglade
et al., 200654
Animal model of
depression
Adult mice 10 mg/kg or 40 mg/kg Fluoxetine 18 mg/day 5 per group Both agomelatine and fluoxetine
increased swimming duration,
antidepressant-like effect
Rainer et al.,
201164
Agomelatine at both doses
increased home cage activity
and ratio of night over day;
normalized the disturbances of
circadian rhythms
At both doses of agomelatine,
increased the number of DCX+
cells both in dorsal and ventral
hippocampal regions, an index
of antidepressant action
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of agomelatine in resynchronizing disturbed circadian
rhythms are attributed to its actions on MT1 and MT2
melatonin receptors present in the SCN. This chrono-
biotic property of agomelatine is regarded as one of the
main underlying factors in the antidepressant effects of
agomelatine.61
Chronic social stress is one of the main triggering
factors for the development of depressive disorders. On
this basis, an animal model has been developed using
tree shrews. Subordinate animals were subjected to
psychosocial conflict daily by exposing them to domi-
nant animals for 1 hour. The intensity of psychosocial
stress in subordinate tree shrews was demonstrated by
pronounced elevation of urinary cortisol levels, which
reflects the sustained activation of the hypothalamic-
pituitary-adrenal (HPA) axis. Chronically stressed tree
shrews were injected with agomelatine 40 mg/kg for 28
days. Agomelatine treatment allowed subordinate ani-
mals to remain under psychosocial conflict situations
without stress and normalized the activity of the HPA
axis, as shown by the reduction of urinary cortisol
levels.62 By using impulse-related behavior, rats were
trained in a T-maze and allowed to choose between two
magnitudes of reward: immediate but small reward
(getting two pellets) versus delayed but large reward
(getting 10 pellets). The behavior of the rats was ob-
served after administration of agomelatine (10 mg/kg and
30 mg/kg doses), melatonin 3 mg/kg and 10 mg/kg
doses, clomipramine 8 mg/kg, fluvoxamine 4 mg/kg, and
GR205171 (substance P receptor antagonist) 10mg/kg and
30 mg/kg. Agomelatine, clomipramine, fluvoxamine,
and GR205171 significantly increased the number of
choices of the large-but-delayed reward. This delayed-
gratification response chosen by those with agomelatine
and other drugs reveals their ability to improve impulse-
control, regarded as an antidepressant effect.63 By using
the chronic corticosterone animal model of depression
and anxiety state (CCAMD), the behavioral consequen-
ces of either chronic agomelatine (10 mg/kg–40 mg/kg
per day) or fluoxetine (18 mg/kg per day) were assessed
in a number of paradigms such as the forced-swimming
test, open-field paradigm, novelty-suppressed feeding
(NSF), and the splash test (ST). Also, the effects of
agomelatine on neurogenesis in the ventral and dorsal
hippocampal regions were analyzed. Both agomelatine
and fluoxetine were administered for a period of 4
weeks. Results of this study from the forced-swimming
test, a well-recognized screening test for depression,
shows that agomelatine at both doses (10 mg/kg and 40
mg/kg per day) and fluoxetine increased mobility
duration in corticosterone- and noncorticosterone-
treated rats. All multiple behavioral parameters with
agomelatine and fluoxetine were found effective in re-
versing depression/anxiety-like phenotypes induced by
excess glucocorticoids.64 The effect of agomelatine also
was assessed on dorsal and ventral hippocampal regions.
The ventral hippocampal region is implicated in anxiety
and mood regulation,65,66 whereas the dorsal hippocam-
pus is concerned with spatial memory. Assessment of the
effects of agomelatine or fluoxetine on neurogenesis of
dorsal and ventral hippocampal regions revealed that cell
proliferations in corticosterone-treated rats were similar
in both dorsal and ventral hippocampal regions.64 Ago-
melatinewas able to reverse the decreased cell-proliferation
induced by corticosterone in the whole hippocampal re-
gion. Besides these effects, agomelatine increased the light/
dark ratio and reversed the alterations in this ratio induced
by corticosterone treatment, suggesting the normalization
of disturbed circadian rhythms. Thus, all the parameters
assessed in this study including antidepressant effect,
normalization of disturbed circadian rhythms, and neur-
ogenesis of hippocampal regions strongly suggest ago-
melatine as a new, innovative, antidepressant drug.67
AGOMELATINE’S THERAPEUTIC EFFICACY
IN DEPRESSIVE AND ANXIETY DISORDERS
The first report on the clinical efficacy of agomelatine in
the treatment of MDD was undertaken by Loo and his
associates (2002).14 The report is based on the clinical
trials undertaken in multi-national, multi-center, double-
blind, placebo-controlled investigations involving 711
patients drawn from 102 clinical centers in Belgium, the
U.K., and France. Of these 711 patients, 67.1% met the
Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV) criteria for recurrent MDD, with 33.5% of
patients having an episode of severe intensity. The mean
baseline score on the 17-item Hamilton Rating Scale for
Depression (Ham-D) was 27.4. Either agomelatine (25
mg/day) or paroxetine (20 mg/day) was administered
for a total period of 8 weeks. By using remission analysis,
the authors found that both agomelatine (30.4%) and
paroxetine (25.7%) brought about significant remission
when compared with placebo. Responder analysis (de-
fined as 50%-or-more reduction in the baseline score of
the Ham-D) showed agomelatine to be superior (61.5%)
to placebo (46.3%), whereas paroxetine did not differ
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much (56.3%) from the placebo response. Among the 711
patients, a subpopulation of patients was categorized as
severely depressed (586 patients with Ham-D score.25).
Administration of agomelatine in this subpopulation
produced a significant response, as comparedwith placebo
(p,0.05), whereas the paroxetine response did not differ
much from the placebo effect. In addition to its effects on
depressive symptoms, both agomelatine and paroxetine
reduced anxiety symptoms. Similar to the findings
reported from the above study, a second multi-center
and multi-national study involving 21 centers across
Finland, Canada, and South Africa, involving 212 patients
(age 18–65 years) evaluated the clinical efficacy of
agomelatine.68 In this study, the Ham-D score exceeded
22. This double-blind, placebo-controlled trial of ago-
melatine (25 mg to 50 mg) was carried out for 6 weeks. In
this study, the intent-to-treat (ITT) group consisted of 106
patients. Treatment with agomelatine for 6 weeks was
associated with significant improvement in the clinical
status of the patients (p=0.045) as compared with the
placebo response. Agomelatine (25 mg to 50 mg) reduced
the Ham-D score quite significantly in the severely
depressed subgroup with Ham-D scores exceeding 25.
In this group, the agomelatine response was more ef-
fective than placebo (p=0.024). The significantly higher
rate of responders to agomelatine (49.1%) versus placebo
(34.3%) and the shorter time to first clinical response further
lend support to the view that agomelatine is effective
especially in patients with greater symptom severity.
The availability of antidepressants with efficacy in
severely depressed patients is very important from the
clinical point of view because this group is relatively
resistant to current antidepressant therapy, which relies
heavily on SNRIs or SSRIs.69 Hence, it is suggested that
the greater clinical response seen with agomelatine when
compared with that of other antidepressants (SSRIs)
points to the superior efficacy of agomelatine over these
other antidepressants. In another study, carried out for
12 weeks in 277 subjects, the patients were randomized
to receive agomelatine at a dose of 50 mg/day or
venlafaxine XR (extended release) at two different doses,
namely, 75 mg/day for the first 2 weeks and then
increased to 150 mg. The rates of remission were found to
be 73% for agomelatine and 67% for venlafaxine-XR-
treated patients. In a flexible-dosing, 6-week trial in 167
patients, subjects were assigned to receive either ago-
melatine (25 mg–50 mg) or venlafaxine (75 mg–150 mg)
in the immediate-release form. A significant reduction
in Ham-D scores was found in both groups, with
agomelatine reducing the Ham-D score from 25.9 (SD:
3.2) to 9.0 (SD: 5.4), and venlafaxine reducing the Ham-D
score from 26.0 (SD: 3.3) to 8.9 (SD: 5.2); the response
rateswere, respectively, 76% and 71% for agomelatine and
venlafaxine immediate-release.15,70 To evaluate the sleep
efficacy of agomelatine, a placebo-controlled, double-
blind study was undertaken in 332 patients with MDD
for a period of 6 weeks. Agomelatine was administered
at a dose of 25 mg–50mg/day, and venlafaxinewas given
at a dose of 75 mg–150 mg/day. Although sleep quality,
as measured by the Leeds Sleep Evaluation Questionnaire
(LSEQ), was found better with agomelatine, the antide-
pressant effect was found similar for both drugs.67
Agomelatine’s superiority in treating patients with
MDD was studied in another 6-week, double-blind,
parallel-group study, involving 238 patients.13 Agome-
latine was administered at 25 mg/day to these patients,
and this dose was raised to 50 mg/day after 2 weeks
in patients who showed negligible improvement. Ago-
melatine was found to be significantly (p,0.001) superior
to placebo, with a difference of 3.44. The response rate
was 54.3% (agomelatine) to 35.5% (placebo). Agomelatine
improved depressed mood and sleep items of the Ham-D
score quite considerably. The drug was well tolerated and
found to be safe in these patients.13
Evaluation of the efficacy of agomelatine on de-
pressive symptoms in patients with major depressive
disorder was carried out in an open-label study of 30
MDD patients receiving flexible doses of 25 mg–50 mg/
day. Of these, only 24 patients (80%) completed 8 weeks
of treatment. Agomelatine treatment produced an early
response, and significant improvement was noted in all
these patients, as seen in Ham-D scores. Moreover, the
effect of agomelatine in improving anhedonia was noted
for the first time in this study.71
The efficacy of agomelatine in preventing the re-
lapse of depressive symptoms and improving the clinical
status of patients with MDD was assessed in a 32-week
study on 165 patients. In this study, patients with DSM-IV
major depressive disorder who responded to 8- to 10-
week administration of agomelatine (25 mg–50 mg/day)
were randomly assigned to receive continuation of
treatment with agomelatine (N=165) or placebo (N=174)
for the treatment period of 24 weeks. The main outcome
was time-to-relapse. During this 6-month evaluation per-
iod, the incidence of relapse was found to be significantly
lower in patients who continued their treatment with
agomelatine than those who switched over to placebo
(p=0.0001). The cumulative relapse rate with agomelatine
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was 21.7%; and for placebo, it was 46.6%. The findings of
this study support the concept that agomelatine is an
effective and safe antidepressant for continuation therapy.
This long-term study confirms the earlier reports of
agomelatine’s efficacy for short-term therapy.13
Agomelatine 25 mg/day was also used as an ad-
junctive treatment along with either lithium (N=14) or
valpromide (N=7) in an open-label study of bipolar I
patients. Agomelatine was administered for a minimum
period of 6 weeks, followed by optimal extension up to
an additional 46 weeks. Using intent-to-treat data, it was
found that 81% of the patients met the criteria for
marked improvement. Patients belonging to the severe
category of depression, with Ham-D score over 25.2
(47.6% of the total number of patients), responded as
early as the first week of treatment. Nineteen patients
entered the optional extension for a mean of 211 days
(6–325 days), and, of these, 11 patients completed a
1-year extension of treatment. Agomelatine was found to
be an effective antidepressant in this study.72 (See Table
2 for a listing of studies on depression treatment.)
Besides being effective in treating MDD and bipolar I
disorder, agomelatine also has been tried for depressed
patients with seasonal affective disorder (SAD). In this
open-label study the efficacy of agomelatine (25 mg/
day) was evaluated for a period of 14 weeks. Assessment
of agomelatine’s efficacy was evaluated by using various
psychometric scales, including the Structured Interview
Guide for the Hamilton Depression Rating Scale (SAD
version; SIGH–SAD); the Clinical Global Impression of
Severity (CGI–S); the Clinical Global Impression of
Improvement (CGI–I); the Circascreen, a self-rating scale
for the assessment of sleep and circadian-rhythm dis-
orders; and the Hypomania Scale. Agomelatine use in
these patients caused a progressive and statistically
significant decrease in SIGH–SAD, CGI–S, and CGI–I
scores beginning in the second week of treatment. Also,
the scores on the Circascreen improved quite sub-
stantially after agomelatine (p,0.001). Treatment with
agomelatine for 14 weeks yielded a response rate of
75.7% (defined as a SIGH–SAD score ,50% of the
baseline value) and a remission rate (SIGH–SAD ,8) of
70.3% in the intent-to-treat sample. The efficacy of
agomelatine in treating patients with seasonal affective
disorder was demonstrated in this study. The drug was
well tolerated throughout the study, and there was only
TABLE 2. Antidepressant Effects of Agomelatine: Clinical Studies
Agomelatine
Dose Illness N Patients Type of Study
Duration
of Study Antidepressant Response Author
25 mg/day MDD 711 Double-blind, placebo-
controlled
8 weeks More effective than placebo Loo et al., 200214
50 mg/day Also in severely depressed
patients
25 mg/day MDD 212 Placebo-controlled 6 weeks More effective in depressed
and severely depressed
Kennedy & Emsley,
20061550 mg/day
25 mg/day MDD 15 Open-label
(polysomnogram and
electroencephalogram)
6 weeks Improved sleep Quera-Salva et al.,
200786
25 mg/day SAD 37 Open study 14 weeks Remission was sustained Pjerk et al., 2007185
25 mg/day MDD 238 Double-blind, placebo-
controlled
6 weeks Both depressive and sleep
symptoms improved
Olié & Kasper, 2007186
25 mg/day MDD 332 Placebo-controlled 6 weeks Effective antidepressant
response and improved
sleep quality
Lemoine et al., 200767
50 mg/day
25 mg/day Depressed
bipolar I
21 Open-label study with
lithium or valpromide
6 weeks Improved depression Calabrese et al., 200772
14 with lithium
and 7 with
valpromide
25 mg/day and
50 mg/day
GAD 121 Randomized, double-
blind, placebo
controlled
12 weeks Significantly superior
to placebo
Stein et al., 200875
50 mg/day MDD 137 Double-blind 12 weeks Antidepressant efficacy
was superior
Kennedy et al., 200870
25 mg/day MDD 339 Double-blind, placebo-
controlled
8 & 24 weeks Very effective
antidepressant effect
Goodwin et al., 200913
50 mg/day
25 mg/day–
50 mg/day
MDD 30 Open-label study 8 weeks Significant response Di Giannantonio et al.,
201171
MDD: major depressive disorder; SAD: seasonal affective disorder; GAD: generalized anxiety disorder.
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one report of an adverse effect, mild fatigue, showing
thereby that the overall rating of agomelatine is good.73
Agomelatine has been found effective not only in
animal models of depression but also in animal models
of anxiety.16,74 The clinical efficacy of agomelatine has
also been studied in 121 DSM-IV GAD patients ran-
domized to agomelatine (25 mg–50 mg/day) or placebo
for 12 weeks. Analysis of covariance of change in the last
Hamilton Rating Scale for Anxiety (Ham–A) score from
the baseline score demonstrated significant superiority
of agomelatine in a 25 mg–50 mg/day dose, as com-
pared with placebo. From this finding, it was concluded
that agomelatine is an effective therapeutic drug for the
treatment of generalized anxiety disorder.75
AGOMELATINE IN OTHER DISORDERS
Recently, agomelatine has been used in some other dis-
orders, such as migraine and familial insomnia in a study
conducted on 20 patients, age 23–45 years, with migraine.
Agomelatine use, in a 25-mg dose for 3months, decreased
migraine attacks effectively and also reduced depression
severity, with normalization of night sleep.76 In yet
another study in a patient with fatal familial insomnia
(FFI), agomelatine in a 25-mg dose improved slow sleep
and sleep efficiency.77
SAFETY AND TOLERABILITY OF AGOMELATINE
Agomelatine exhibits an excellent safety and tolera-
bility record when compared with other antidepressants
currently in use. Its safety record is close to that of
placebo (5.9% versus 3.5%). The frequency of adverse
effects such as headache, anxiety, abdominal pain, and
diarrhea were less than that of placebo. The discontin-
uation rate for adverse effects with agomelatine was
8.0%, which was close to that of placebo, 6.55%, showing
thereby the excellent tolerability record of agomelatine.14
Emergent adverse events such as gastrointestinal, car-
diovascular, and body weight problems were generally
lower than that of vanlafaxine or sertraline.78Most of the
currently available antidepressants induce sexual dys-
function that often interferes with recovery from the
depressive episode.79 All antidepressants affect most
phases of sexual activity, such as desire, arousal, and
ejaculation in men.44 In studies on agomelatine-treated
patients, only a few reports of sexual dysfunction have
been documented.78,80
AGOMELATINE’S ANTIDEPRESSANT EFFECT:
MECHANISM OF ACTION
It is a longstanding dictum that all available antidepres-
sants exert their therapeutic actions mainly by the
modulation of monoaminergic mechanisms in the brain.
Depressive patients often experience a number of sleep
disturbances, like difficulty in falling asleep, staying
asleep, disturbed nocturnal sleep, early-morning awak-
ening, etc.36 A number of studies point out that depres-
sion is linked to disturbances in circadian rhythms;
hence, an antidepressant that benefits sleep quality and
resets disturbed circadian rhythms will have more
beneficial therapeutic antidepressant efficacy. As noted
in the earlier sections, agomelatine is a melatonergic
agonist of MT1/MT2 melatonergic receptors, with
antagonism of 5-HT2C serotonergic receptors. The thera-
peutic efficacy of agomelatine in depressive disorders is
attributed to its action on MT1 and MT2 melatonergic
receptors, present largely in the SCN of the hypothala-
mus, and also to its 5-HT2C antagonism.
54,81 5-HT2C
receptors are concentrated in the frontal cortex, amyg-
dala, hippocampus, cortico-limbic structures, and SCN,
and these structures are involved in the regulation of
mood and cognition.82Antidepressants in use have been
shown to exert their therapeutic effects by decreasing the
number of 5-HT2C receptors;
83 but agomelatine’s supe-
riority over other antidepressants with 5-HT2C antago-
nism has been related to its effects in “improving sleep
and daytime alertness.”84,85 As we have seen earlier,
agomelatine exerted a superior antidepressant effect in
animal models of depression, whereas neither melatonin
nor 5-HT2C antagonist antidepressants could mimic the
antidepressant effect of agomelatine.54 Activation of
both melatonergic MT1 and MT2 receptors and blockade
of 5-HT2C receptors are essential for agomelatine’s
antidepressant effect.17 In patients with MDD, ago-
melatine has been shown to improve all aspects of the
sleep–wake cycle as early as during the first week of
treatment itself.86 This action of agomelatine in improv-
ing sleep efficiency and normalizing disturbed sleep–
wake cycles is an important mechanism by which
agomelatine exerts its therapeutic antidepressant ef-
fect.39 Current antidepressants that are in clinical use
today, especially SSRIs, cause profound sleep disturban-
ces and exacerbate insomnia. Hence, sleep medications
are used as a combination therapy along with anti-
depressants when treating patients with depressive
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disorders. As has been discussed earlier, all antidepres-
sants elevate daytime mood in depressed patients by
activating CNS arousal mechanisms, but since this effect is
sustained throughout the 24-hour period, they can cause
disruption of sleep mechanisms.42 The effectiveness of the
novel antidepressant agomelatine is considered to be due
to its dual actions of preserving sleep quality and efficiency
through melatonergic MT1 and MT2 activation and ele-
vating mood and activity through serotoninergic 5HT2C
antagonism. Agomelatine antagonizes the 5-HT2C recep-
tors both during daytime and at night.
CIRCADIAN PACEMAKER IN THE
SUPRACHIASMATIC NUCLEI (SCN)
All living organisms exhibit robust physiological and
biochemical rhythms.87 These rhythms depend upon the
presence of clock genes in the cells and are synchronized
by a master clock located in the suprachiasmatic nuclei
(SCN) of the hypothalamus.88 Circadian periodicity ge-
nerated by the SCN is approximately 24.2 hours89 and
is synchronized to exactly 24 hours by the environmental
light–dark cycle that acts through the retina and the
retino–hypothalamic tract.90 Neurons in the SCN, as
has been earlier noted, contain both MT1 and MT2
melatonin receptors. The circadian rhythm of melatonin
secretion is regulated by the SCN, and melatonin is
also a feedback regulator of the SCN by acting through
both MT1 and MT2 melatonergic receptors. Both phase
and amplitude of circadian rhythms are influenced
by melatonin, acting through these receptors. Phase-
shifting of circadian rhythms by melatonin are effected
through MT2 melatonergic receptors,
91,92 whereas the
amplitude of circadian rhythms as studied by neuronal
firing rates in SCN are influenced by melatonin acting
through MT1 melatonergic receptors.
93,94 As depressive
disorders have been suggested to be due to disorders of
circadian rhythms, including sleep–wake rhythms, it is
likely that the actions of agomelatine in resetting the
disturbed rhythms and sleep–wake rhythms is mediated
through melatonergic receptors of the SCN.
The role of melatonin receptors in mediating antide-
pressant effects has been inferred from studies carried out
on MT1 melatonin-receptor knockout mice (MT12/2).
MT1melatonin-receptor knockoutmice exhibit depression-
like behavior. Both male and female melatonin-receptor
knockout mice spent significantly more time in immo-
bility in the forced-swimming test, a test that is usually
employed for studying animal models of depression.86
Given that the disruptions in the circadian rhythms and
sleep–wake cycles correlate with the severity of depres-
sion,85 the chronotherapeutic effect of agomelatine inMDD
was evaluated. Agomelatine caused an increase in relative
amplitude of the circadian rest–activity cycle by the end of
Week 1, and it ran parallel with improvements of sleep
efficiency and sleep latency from Week 1 to Week 6.
Depression and anxiety symptoms were very much
improved in these patients, along with circadian rhythm
and sleep improvements.75 This study supports the
concept that agomelatine’s specific target of action is
mainly on MT1/MT2 melatonergic receptors in the SCN,
and, thereby, it corrects the underlying abnormality of the
disturbed circadian rhythm and sleep–wake cycles of
patients with depressive disorders. Hence, the important
component of agomelatine’s antidepressant effect resides
in the mechanism of improving sleep efficiency coupled
with the correction of disrupted circadian rhythms.95
Recent review studies have presented evidence supporting
the clinical supremacy of agomelatine as an effective
antidepressant,96 because of its early onset of action,97 low
relapse rate,98 and targeting of melatonergic receptors for
normalizing disturbed sleep and circadian rhythm.99–102
NEUROGENIC EFFECTS OF AGOMELATINE:
ANOTHER POSSIBLE MECHANISM FOR ITS
ANTIDEPRESSANT EFFECT
Recent preclinical studies have demonstrated that
agomelatine, like other antidepressants, such as SSRIs
and tricyclics, increase cell proliferation in the dentate
gyrus of adult rats103,104 Chronic agomelatine treatment
reversed the decreased neurogenesis of glucocorticoid
receptor-impaired mice (GR-mice), an animal model of
depression,105 and this effect was shown to occur mainly
in the ventral hippocampus.103,104 The ventral hippo-
campus is implicated in anxiety and mood-regulation,
and the dorsal hippocampus is concerned with spatial
memory.65,66,106 Using corticosterone-treated mice
(an animal model of depression and anxiety), the ef-
fects of agomelatine or fluoxetine were tested on
dendritic maturation in both dorsal and ventral hip-
pocampal regions. Although both antidepressants
modified the maturation index, the number of double
cortin expression cells (DCX+ cells) with tertiary den-
drites was increased with agomelatine (10 mg/kg–40
mg/kg day) only in the ventral hippocampal region of
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corticosterone-treated animals.64 Agomelatine induced
an early acceleration of cell maturation at 8 days of
development.104 Previous studies point out that the
earliest time-point at which an antidepressant (fluoxe-
tine) caused cell maturation was 21 days.107 From this
study, it is evident that agomelatine has a more rapid
action on cell maturation than SSRIs or any other
monoaminergic antidepressants.104 Because agomelatine
caused dendritic maturation in animal models of
depression/anxiety, with earlier onset of action, and also
demonstrated circadian-rhythm regulatory effects in
animal models of depression, it contributes a distinctive
profile in its antidepressant action.64 As the ventral
hippocampus projects to the prefrontal cortex and
amygdala, these agomelatine data support the view that
the ventral hippocampus is involved in the emotional
circuitry supporting the control of depressive/anxiety
states.65,108 The ventral hippocampus seems to contain 5-
HT2C receptors, but actions of agomelatine on dendritic
maturation are thought to be mediated through both
melatonergic and 5-HT2C receptors present in the ventral
hippocampus.104 Hence, based on agomelatine’s action
in improving sleep efficiency, resynchronizing disrupted
circadian rhythms, and enhancing dendritic maturation,
demonstrated in both preclinical and clinical studies, it is
clear that agomelatine has a novel antidepressant effect,
with a rapid onset of action and greater clinical efficacy.
The effects of 25 mg/day–50 mg/day of agomelatine
(N=154) or sertraline (50 mg/day–100 mg/day) was
studied in patients with MDD over a period of 6 weeks
in a randomized, double-blind study. With agomelatine,
significant improvement in the relative amplitude of the
rest–activity cycle was observed in the first week (p=0.01);
improvements in sleep quality (p,0.001) and sleep
efficiency (p,0.001) were also observed from Week 1 to
Week 6. Depressive symptoms improved considerably
more with agomelatine (p,0.05) than with sertraline. This
study supports the idea that agomelatine is more efficient
in improving sleep parameters, the circadian rest–activity
cycle, and depressive symptoms than sertraline.109
ADDITIONAL HEURISTIC MELATONERGIC
ANTIDEPRESSANT AND ANXIOLYTIC
MECHANISMS
The effects of improved sleep and MT1/MT2 stimulation
can also exert important effects on depressive and
anxiogenic mechanisms that include oxidative stress,
nitric oxide metabolism, mitochondrial function, neuro-
inflammation, neurotrophins (e.g., BDNF and GDNF),
dopaminergic integrity, cyclic nucleotides (cAMP and
cGMP), clock gene expression (Clock and NPAS2), heat
shock proteins (HSP27), and apoptosis.
As mentioned above, sleep-enhancing effects may
be important to agomelatine’s therapeutic effects. More
specifically, improvement of sleep may target certain
mechanisms implicated in depressive and anxiety
pathophysiology. Impaired sleep has been shown to
adversely affect oxidative stress,110 mitochondrial in-
tegrity and function,111 and inflammation,112 mecha-
nisms that play pathophysiological roles in mood and
anxiety disorders. Specifically, oxidative stress has been
related to major depression,113–117 especially with regard
to the hippocampus.118 Oxidative stress has also been
implicated in bipolar disorder119–125 and anxiety.126–128
Mitochondrial perturbations have been linked to major
depression114,129–131 and bipolar disorder.129,130,132 In-
flammation has also been associated with major de-
pression116,131,133–135 and bipolar disorder.132,136–138 For
example, sleep deprivation is thought to trigger an
inflammatory and stress response in the brain through
gene induction.112 Improvement of sleep by agomelatine
can therefore improve oxidative, mitochondrial, and
inflammatory processes that contribute to the patho-
physiology of these disorders.
Besides the SCN and several other hypothalamic
regions, melatonin receptors can also be found in the
paraventricular nucleus of the thalamus, parabrachial
nuclei, and olfactory bulb in mice.139 In lizards, they
are observed in visual pathway centers, the striatum,
habenula, mammillary nucleus, septum, interpeduncu-
lar nucleus, medial cortex, and dorsal cortex.140 In
rabbits, MT receptors were found in the cerebral cortex,
cingulate gyrus, and hippocampus.141 MT1 receptors are
found in human cerebellar neurons.142MT2 receptors are
distributed in the human hippocampus143 and cerebellar
glia.142 Limbic structures, striatum, cerebellum, hippo-
campus, and cingulate gyrus have each been demon-
strated to play important roles in human mood
disorders. Effects on MT1 and MT2 receptors in these
areas might therefore mediate the antidepressant and
anxiolytic effects of agomelatine.
Direct agonist effects of agomelatine on melatonin
MT1 and MT2 receptors may also remedy relevant
pathophysiological processes by protecting against
oxidative stress, including effects on nitric oxide (NO)
levels. Protection against oxidative stress appears to be
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mediated through MT1
144–147 and possibly, MT2
146,147
receptors. NO is important in mediating major depres-
sion148 and bipolar depression149 pathophysiologies. In
bipolar depression, serumNO is elevated, and normalizes
with antidepressant treatment over 30 days.149 In rat
intestinal synaptosomes, melatonin reduced NO synthase
activity, an effect possibly mediated by the MT1 re-
ceptor.150 MT1 and MT2 receptor stimulation also in-
dependently increases brain-derived neurotrophic factor
(BDNF). BDNF is involved in the pathophysiologies
of both major depression151–153 and bipolar depres-
sion.154,155 Although stimulation of either MT1 or MT2
receptors increase BDNF concentrations,156 agomelatine
additionally increases BDNF through a synergistic effect
of MT1, MT2, and 5HT2c receptors.
104,157
As noted earlier, MT1 stimulation inhibits adenylyl
cyclase cAMP production,158 consistent with cAMP
down-regulation that has similarly been correlated with
the antidepressant effects of salbutamol159 and imipra-
mine.160 MT1 receptor activity in particular has been
correlated with neurotrophic increases in BDNF,156,161
glial-derived neurotrophic factor (GDNF),161 and tyrosine
hydroxylase.162 There is evidence that GDNF levels are
reduced in depressive disorders163,164 and that increased
GDNF-release constitutes an antidepressant mecha-
nism.165 GDNF further promotes dopaminergic neuron
survival;166 these neurons are involved in mediating
depressive symptomatology.167–169A reduction of striatal
dopamine-transporter binding is observed in seasonal
affective disorder,170 and dopamine seems to play a role
in the semiology of this disorder.171 These findings of
improved dopaminergic neuron survival166 and increases
in tyrosine hydroxylase seen with MT stimulation162
suggest protective and trophic effects on mood-related
dopamine neurons. MT1 effects on clock genes have also
been suggested to participate in the pathobiology of
mood- and dopamine-related behaviors.172 MT1 stimula-
tion down-regulates Clock and up-regulates neuronal
PAS-domain protein 2 (NPAS2) mRNA expression in
mouse striatum.172 Subjects with depression exhibit
increased leukocyte clock mRNA expression.173 Several
Clock174–176 and NPAS2174,177,178 single-nucleotide poly-
morphisms have been linked to MDD174 and seasonal
affective disorder,177,178 as well as to bipolar depres-
sion174,177,178 symptoms175 and recurrence.176
MT2 receptor activation inhibits NO-induced increases
in cyclic GMP179—of interest because plasma cGMP levels
have been noted to be increased in patients develop-
ing depression after receiving 6 weeks of interferon
treatment.133 MT2 receptor-stimulation increases BDNF
concentrations,156 induces heat-shock protein HSP27, and
prevents apoptosis,180 perhaps related to agomelatine’s
antidepressant effect,115 since apoptotic markers are
increased in depressive disorders113,181,182 and are nor-
malized by antidepressant treatment.182
Thus, multiple effects of agomelatine over a wide
range of pathophysiological processes may bring about
the observed benefits in major depression, bipolar dis-
order, seasonal affective disorder, and generalized
anxiety disorder.
A last observation regarding the mechanism(s) of
action of agomelatine should be kept in mind. Ago-
melatine displays a similar dissociation constant (Kd) for
MT1/MT2melatonin receptors to that of melatonin itself;
that is, 10 nM at 10 p.m.102 This fact implies that doses of
1 mg–3 mg melatonin or agomelatine are enough to
saturate both MT1/MT2 receptors in the body. However,
the therapeutic doses of agomelatine normally range
between 25 mg/day and 50 mg/day, suggesting that an
effect other than binding to MT1/MT2 receptors (and 5-
HT2c receptors) might take place. In this regard, it was
recently reported that melatonin does not move freely
through the body, as has earlier been suggested. Instead,
subcellular melatonin distribution is a regulated pro-
cess, even in the brain;183 so studying the intracellular
distribution of agomelatine may yield important in-
formation regarding intracellular effects of this melato-
nin analog.
CONCLUSIONS
Agomelatine, the melatonergic agonist, has demon-
strated its antidepressant effect in a number of
preclinical studies undertaken on animal models of
depression. It has also demonstrated its potency in
resynchronizing disturbed circadian rhythms in experi-
mental animals, and this effect is attributed to ago-
melatine’s actions on melatonergic receptors in the
suprachiasmatic nucleus. In more than 11 clinical studies
undertaken in Europe, involving a large number of
patients from different centers, agomelatine has been
found to be effective in reducing depressive symptoms,
improving sleep quality and efficiency, and re-setting the
disturbed circadian rhythm. Unlike the other antidepres-
sants, agomelatine exhibited sleep and antidepressant
effects within a week of its administration. In a number
of studies, agomelatine’s clinical efficacy was sustained
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through 24 weeks of administration without any adverse
side effects. Treatment of depressive disorders, MDD,
bipolar I disorder, SAD, and GAD was not associated
with co-prescription of hypnotic-sedatives. A recent
review summarized the clinical efficacy of agomelatine
in various depressive symptoms, such as 1) core
symptoms; 2) sleep symptoms; 3) anxiety; 4) retardation;
5) somatic symptoms; 6) anxiety; and 7) work and
alertness. Moreover, agomelatine has been shown to be
efficient in severe depression.184 The mechanism of
agomelatine’s antidepressant effect is attributed to its
actions on melatonergic receptors (MT1/MT2) present
in the SCN, as well as to its 5-HT2C antagonism. By
improving sleep and resynchronizing disrupted circa-
dian rhythms, agomelatine exerts its novel mode of
antidepressant action. Moreover, as demonstrated by
preclinical studies, agomelatine‘s antidepressant effect is
attributed to its neurogenic effects in the dorsal and
ventral hippocampal regions. Although this effect is
shared by other antidepressants, such as SSRIs, ago-
melatine alone has a rapid effect on neurogenesis. On the
basis of all available clinical studies, we can conclude that
agomelatine is an effective antidepressant with a rapid
onset of action not only in MDD patients in general, but
also in patients with severe MDD, bipolar I disorder,
SAD, and generalized anxiety disorder. Unlike other
antidepressants, agomelatine does not causeworsening of
sleep disturbances or sexual dysfunction and is associated
with fewer side effects than are seen with placebo
therapy.
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